At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 165 enrolled
Drug / intervention
Pacritinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
In Brief
A Phase 2 clinical trial evaluating Pacritinib for Primary Myelofibrosis and 2 related conditions. Completed, enrolled 165 participants across 62 sites in 8 countries.
Detailed Summary
This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System \[DIPSS\] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis
CountriesFrance, Hungary, Italy, South Korea, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
Primary CompletionSep 2019
First PostedMay 2021
TodayJul 2026
First PostedMay 12, 2021
Enrollment StartJul 31, 2017
Primary CompletionSep 4, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.1 years ago
Interventions
Pacritinibdrug
Pacritinib